Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer

Christina Rangel, Haim Matzkin, Mark S. Soloway

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

One hundred eleven patients with endocrine-refractory Stage D prostate cancer were treated with weekly administration of 20 mg/m2 body surface area of doxorubicin hydrochloride (Adriamycin). Fifty-seven were part of a randomized study comparing doxorubicin and prednisone to prednisone alone. There were significantly more subjective responders in the doxorubicin group than in the prednisone group (p < 0.01). The number of patients with evidence of stable disease was also higher during the chemotherapy arm compared with prednisone alone (p = 0.02). Patients taking doxorubicin had a slightly longer period of stable disease than did those taking prednisone (p = 0.08). Overall survival, however, was not prolonged (p = 0.26). Fifty-four patients took part in an open trial and 69 percent responded to treatment. All of these had clinical improvement. Side effects were minimal with cardiotoxicity noted in less than 15 percent among patients with side effects. Over 35 percent had no side effects. Thus single agent, weekly doxorubicin therapy as evaluated in our experience, while well tolerated and of subjective benefit, does not provide the patient with a significant longer progression free survival or improved overall survival.

Original languageEnglish
Pages (from-to)577-582
Number of pages6
JournalUrology
Volume39
Issue number6
DOIs
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Doxorubicin
Prednisone
Prostatic Neoplasms
Hormones
Survival
Body Surface Area
Disease-Free Survival
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer. / Rangel, Christina; Matzkin, Haim; Soloway, Mark S.

In: Urology, Vol. 39, No. 6, 01.01.1992, p. 577-582.

Research output: Contribution to journalArticle

Rangel, Christina ; Matzkin, Haim ; Soloway, Mark S. / Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer. In: Urology. 1992 ; Vol. 39, No. 6. pp. 577-582.
@article{e2b674c2be45455e9c8368b4e13b2390,
title = "Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer",
abstract = "One hundred eleven patients with endocrine-refractory Stage D prostate cancer were treated with weekly administration of 20 mg/m2 body surface area of doxorubicin hydrochloride (Adriamycin). Fifty-seven were part of a randomized study comparing doxorubicin and prednisone to prednisone alone. There were significantly more subjective responders in the doxorubicin group than in the prednisone group (p < 0.01). The number of patients with evidence of stable disease was also higher during the chemotherapy arm compared with prednisone alone (p = 0.02). Patients taking doxorubicin had a slightly longer period of stable disease than did those taking prednisone (p = 0.08). Overall survival, however, was not prolonged (p = 0.26). Fifty-four patients took part in an open trial and 69 percent responded to treatment. All of these had clinical improvement. Side effects were minimal with cardiotoxicity noted in less than 15 percent among patients with side effects. Over 35 percent had no side effects. Thus single agent, weekly doxorubicin therapy as evaluated in our experience, while well tolerated and of subjective benefit, does not provide the patient with a significant longer progression free survival or improved overall survival.",
author = "Christina Rangel and Haim Matzkin and Soloway, {Mark S.}",
year = "1992",
month = "1",
day = "1",
doi = "10.1016/0090-4295(92)90023-P",
language = "English",
volume = "39",
pages = "577--582",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer

AU - Rangel, Christina

AU - Matzkin, Haim

AU - Soloway, Mark S.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - One hundred eleven patients with endocrine-refractory Stage D prostate cancer were treated with weekly administration of 20 mg/m2 body surface area of doxorubicin hydrochloride (Adriamycin). Fifty-seven were part of a randomized study comparing doxorubicin and prednisone to prednisone alone. There were significantly more subjective responders in the doxorubicin group than in the prednisone group (p < 0.01). The number of patients with evidence of stable disease was also higher during the chemotherapy arm compared with prednisone alone (p = 0.02). Patients taking doxorubicin had a slightly longer period of stable disease than did those taking prednisone (p = 0.08). Overall survival, however, was not prolonged (p = 0.26). Fifty-four patients took part in an open trial and 69 percent responded to treatment. All of these had clinical improvement. Side effects were minimal with cardiotoxicity noted in less than 15 percent among patients with side effects. Over 35 percent had no side effects. Thus single agent, weekly doxorubicin therapy as evaluated in our experience, while well tolerated and of subjective benefit, does not provide the patient with a significant longer progression free survival or improved overall survival.

AB - One hundred eleven patients with endocrine-refractory Stage D prostate cancer were treated with weekly administration of 20 mg/m2 body surface area of doxorubicin hydrochloride (Adriamycin). Fifty-seven were part of a randomized study comparing doxorubicin and prednisone to prednisone alone. There were significantly more subjective responders in the doxorubicin group than in the prednisone group (p < 0.01). The number of patients with evidence of stable disease was also higher during the chemotherapy arm compared with prednisone alone (p = 0.02). Patients taking doxorubicin had a slightly longer period of stable disease than did those taking prednisone (p = 0.08). Overall survival, however, was not prolonged (p = 0.26). Fifty-four patients took part in an open trial and 69 percent responded to treatment. All of these had clinical improvement. Side effects were minimal with cardiotoxicity noted in less than 15 percent among patients with side effects. Over 35 percent had no side effects. Thus single agent, weekly doxorubicin therapy as evaluated in our experience, while well tolerated and of subjective benefit, does not provide the patient with a significant longer progression free survival or improved overall survival.

UR - http://www.scopus.com/inward/record.url?scp=0026780343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026780343&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(92)90023-P

DO - 10.1016/0090-4295(92)90023-P

M3 - Article

VL - 39

SP - 577

EP - 582

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -